Free Trial

Opus Genetics (IRD) Competitors

Opus Genetics logo
$1.02 +0.03 (+2.62%)
Closing price 05/21/2025 04:00 PM Eastern
Extended Trading
$1.01 -0.01 (-0.98%)
As of 05/21/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IRD vs. MOLN, ELDN, OGI, INBX, PRQR, HURA, DMAC, ACIU, IKT, and ESPR

Should you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), DiaMedica Therapeutics (DMAC), AC Immune (ACIU), Inhibikase Therapeutics (IKT), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

Opus Genetics vs.

Opus Genetics (NASDAQ:IRD) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Opus Genetics has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opus Genetics$10.99M4.22-$9.99M-$2.10-0.49
Molecular Partners$2.23M71.63-$69.04M-$1.92-2.06

Molecular Partners received 7 more outperform votes than Opus Genetics when rated by MarketBeat users. However, 100.00% of users gave Opus Genetics an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote.

CompanyUnderperformOutperform
Opus GeneticsOutperform Votes
6
100.00%
Underperform Votes
No Votes
Molecular PartnersOutperform Votes
13
48.15%
Underperform Votes
14
51.85%

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 26.5% of Molecular Partners shares are held by institutional investors. 6.6% of Opus Genetics shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Opus Genetics presently has a consensus target price of $7.33, indicating a potential upside of 618.95%. Molecular Partners has a consensus target price of $12.00, indicating a potential upside of 203.03%. Given Opus Genetics' higher possible upside, research analysts plainly believe Opus Genetics is more favorable than Molecular Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opus Genetics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Molecular Partners
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Opus Genetics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

In the previous week, Molecular Partners had 7 more articles in the media than Opus Genetics. MarketBeat recorded 10 mentions for Molecular Partners and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.50 beat Molecular Partners' score of 0.43 indicating that Opus Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Opus Genetics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Molecular Partners
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Opus Genetics has a net margin of -324.45% compared to Molecular Partners' net margin of -1,043.01%. Molecular Partners' return on equity of -39.31% beat Opus Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Opus Genetics-324.45% -63.65% -56.94%
Molecular Partners -1,043.01%-39.31%-35.46%

Summary

Molecular Partners beats Opus Genetics on 10 of the 19 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRD vs. The Competition

MetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$46.39M$6.52B$5.37B$8.39B
Dividend YieldN/A2.65%5.22%4.10%
P/E Ratio-0.948.9226.8419.71
Price / Sales4.22253.80392.34117.39
Price / CashN/A65.8538.2534.62
Price / Book0.466.466.794.50
Net Income-$9.99M$143.98M$3.23B$248.18M
7 Day Performance7.37%2.03%1.53%0.20%
1 Month Performance38.91%4.11%10.06%12.37%
1 Year PerformanceN/A-2.87%16.72%7.04%

Opus Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRD
Opus Genetics
2.0295 of 5 stars
$1.02
+2.6%
$7.33
+619.0%
N/A$46.39M$10.99M-0.9414Earnings Report
MOLN
Molecular Partners
1.9444 of 5 stars
$4.28
+4.4%
$12.00
+180.4%
+10.6%$172.81M$4.97M-1.99180Earnings Report
Analyst Revision
ELDN
Eledon Pharmaceuticals
2.1569 of 5 stars
$2.87
-0.7%
$12.50
+335.5%
+1.9%$171.86MN/A-1.4310News Coverage
Positive News
Earnings Report
Analyst Revision
Gap Up
OGI
Organigram
0.2575 of 5 stars
$1.28
+8.5%
N/A-30.2%$171.31M$166.12M-3.37860Gap Down
High Trading Volume
INBX
Inhibrx
1.8939 of 5 stars
$11.71
+4.7%
N/A-61.6%$169.51M$200,000.000.00166
PRQR
ProQR Therapeutics
3.1895 of 5 stars
$1.59
-1.2%
$8.75
+450.3%
-9.5%$167.29M$18.91M-4.97180
HURA
TuHURA Biosciences
N/A$3.82
-4.3%
$12.67
+231.6%
N/A$166.86MN/A0.00N/ANews Coverage
Earnings Report
Analyst Revision
DMAC
DiaMedica Therapeutics
1.4867 of 5 stars
$3.83
+4.6%
$8.00
+108.9%
+35.9%$164.14MN/A-6.8420News Coverage
Analyst Revision
Gap Up
ACIU
AC Immune
2.732 of 5 stars
$1.63
-3.0%
$10.00
+513.5%
-50.6%$163.67M$28.30M-3.54140Positive News
Gap Up
IKT
Inhibikase Therapeutics
1.5002 of 5 stars
$2.19
+9.5%
$6.50
+196.8%
+4.2%$162.81M$260,000.00-0.826News Coverage
Gap Down
ESPR
Esperion Therapeutics
3.5568 of 5 stars
$0.80
+0.1%
$6.25
+682.3%
-64.6%$158.30M$259.57M-1.25200High Trading Volume

Related Companies and Tools


This page (NASDAQ:IRD) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners